Compare AbbVie Inc (ABBV) vs Garmin Ltd. (GRMN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Garmin Ltd. — how do they compare? AbbVie Inc trades at $253.86 (market cap $449.91B), while Garmin Ltd. trades at $244.05 (market cap $47.96B). The key difference: AbbVie Inc is far larger — about 9.4× Garmin Ltd.'s market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | GRMN | |
|---|---|---|
Market Cap | $449.91B | $47.96B |
Sector | Health | Technology |
52-Week High | $261.07 | $267.52 |
52-Week Low | $184.85 | $187.10 |
Enterprise Value | $513.38B | $45.43B |
Dividend Yield | 2.72% | 1.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
Garmin (GRMN) trades at $248.68, up 3.63% today, reflecting strong momentum near its recent highs. The stock exhibits a bullish technical trend, supported by robust fundamentals including a 23.26% net income margin and consistent revenue growth from $4.9B in 2022 to $7.25B in 2025. Recent product launches like LiveScope 2 and positive earnings beats in Q4 2025 and Q1 2026 underscore operational strength.
The outlook remains favorable with a consensus price target of $282.67, though risks include competitive pressures and market volatility. Investment appeal centers on sustained profitability and innovation, but investors should weigh high valuation multiples against growth sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Garmin Ltd.
Garmin produces GPS-enabled hardware and software for five verticals: fitness, outdoors, auto, aviation, and marine. The company relies on licensing mapping data to enable its hardware specialized for often niche activities like scuba diving or sailing. Garmin operates in 100 countries and sells its products via distributors as well as relationships with original equipment manufacturers.
Read more on GRMN →
